GH Research PLC Files 2024 Annual Report

Ticker: GHRS · Form: 20-F · Filed: Feb 27, 2025 · CIK: 1855129

Sentiment: neutral

Topics: annual-report, financials, pharmaceuticals

TL;DR

GH Research PLC dropped its 2024 20-F, check financials for 12/31/24.

AI Summary

GH Research PLC filed its annual 20-F report for the fiscal year ending December 31, 2024. The company, incorporated in L2 and headquartered in Dublin, Ireland, operates in the pharmaceutical preparations sector. Key financial figures reported include Additional Paid-in Capital and Retained Earnings for the fiscal years 2022, 2023, and 2024.

Why It Matters

This filing provides investors with a comprehensive overview of GH Research PLC's financial performance and position for the fiscal year 2024, crucial for understanding the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, GH Research PLC faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the sector.

Key Numbers

Key Players & Entities

FAQ

What were the key financial metrics reported for GH Research PLC in its 2024 20-F filing?

The filing indicates reporting for Retained Earnings, Additional Paid-in Capital, and Reserve of Exchange Differences on Translation for the fiscal years ending December 31, 2024, 2023, and 2022.

Where is GH Research PLC incorporated and headquartered?

GH Research PLC is incorporated in L2 and headquartered in Dublin, Ireland.

What is the Standard Industrial Classification code for GH Research PLC?

The SIC code for GH Research PLC is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for GH Research PLC?

The SEC file number for GH Research PLC is 001-40530.

When was this 20-F filing submitted?

This 20-F filing was submitted on February 27, 2025.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on February 27, 2025 regarding GH Research PLC (GHRS).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing